Sanofi SA (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 215   

Articles published

SNY 53.92 +0.35 (0.65%)
price chart
Sanofi SA (ADR), Evotec Enter Into €250 million Strategic Alliance
Sanofi SA ADR (NYSE:SNY) on Saturday announced to transfer its research facility in Toulouse, France to Evotec AG ADR (OTCMKTS:EVTCY) in a deal worth €250 million.
Dyax Corp. (DYAX) Takeover Talk: Shire PLC (ADR), Sanofi SA (ADR) Among ...
Dyax Corp. (NASDAQ:DYAX) was flagged as an attractive acquisition target by Bloomberg on Wednesday, on the back of its investigational drug that reported promising Phase 1b data at the annual meeting of the European Academy of Allergy and Clinical ...
Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi SA (ADR ...
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent´┐Ż (alirocumab) Injection met its primary endpoint.
GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS), Sanofi SA (ADR) (SNY ...
The stocks include London-based GlaxoSmithKline plc (ADR) (NYSE:GSK), Switzerland-based Novartis AG (ADR) (NYSE:NVS) and France-based Sanofi SA (ADR) (NYSE:SNY). The veteran portfolio manager has an impressive track-record of managing to ...
GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR ...
pills healthcare Jay Taylor: I recently shared with you a story about a billionaire hedge fund manager who has declared war against the pharmaceutical industry and the patents it uses to protect big corporate profits.
Novo Nordisk A/S, Sanofi SA, Merck & Co Top $62 Billion Diabetes Market In ...
According to a report compiled by data analytics firm GlobalData, the 10 leading diabetes drug-makers generated around $62 billion in 2014 global sales, up 5.1% year-over-year (YoY).
Why Sanofi SA (ADR) Doesn't Consider Acquisitions Essential For Future Growth
The French pharmaceutical giant, Sanofi SA (ADR) (NYSE:SNY), after considering various acquisition options, has reached the conclusion that takeovers and various deal-making opportunities would not be the most essential growth driver for the company in ...
Sanofi SA (ADR) (SNY) Upgraded To Outperform By Leerink Partners
Sanofi SA (ADR) (NYSE:SNY) stock was upgraded from a Market Perform rating to an Outperform rating by analysts at Leerink Swann & Company in a research report issued to clients on Tuesday.
Leerink Swann & Company promoted Sanofi SA (ADR) (NYSE:SNY) to an Outplay  Stocks.org
Sanofi SA (ADR): Differing Regulatory Decisions Harm Global Drug Research
The marked difference in the timings of regulatory decisions worldwide regarding new medicines is a pressing issue affecting the profitability of pharmaceutical research, as discussed by Elias Zerhouni, head of research at Sanofi SA (ADR) (NYSE:SNY) on ...
Sanofi SA (ADR) (SNY) Diabetes Drug Sales Disappoint; Trend Expected To ...
Sanofi SA (ADR) (NYSE:SNY) announced that the company's diabetes products saw a larger-than-expected drop in sales due to lower pricing of the company's star drug, Lantus.